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1. Introduction
Cardiovascular disease, primarily encompassing coronary heart disease, hypertensive heart
disease, heart failure, and stroke, is the number one cause of death globally, with 17.3 million
dying from such causes in 2008 and a projected 23.6 million dying from cardiovascular disease
in 2030 [1]. Cardiovascular disease affects 1 in every 3 Americans, or an estimated 83.6 million
people (myocardial infraction, 7.6 million; angina pectoris, 7.8 million; heart failure, 5.1 million;
and stroke of any kind, 6.8 million; high blood pressure, 77.9 million) [2]. Heart disease and
stroke results in over 500,000 and 160,000 deaths, respectively, each year in the United States;
giving rise to an enormous annual economic burden exceeding $312 billion in both direct and
indirect costs [1,2].
Upper gastrointestinal (or dyspeptic) symptoms, often sub-classified as ulcer-like (localized
epigastric pain or nocturnal/fasting pain), gastroesophageal-like (heartburn or regurgitation)
or dysmotility-like dyspepsia (postprandial fullness, early satiety, diffuse epigastric pain,
belching or abdominal distention) are also highly prevalent worldwide with an average 3-
month prevalence rate across an international sample of survey respondents of about 28%, but
with higher rates in some countries such as the United States (41.8%) [3] and lower rates in
others (Japan’s rate=9.4%). Clinically-relevant upper gastrointestinal symptoms have been
found to result in high healthcare utilization [4,5]; as noted in one study [4] which found 20%
of affected patients visited a physician’s office during the 3-months prior to being surveyed,
2% were hospitalized, nearly half used an over-the-counter medication and 27% were prescri‐
bed at least one medication to address their symptoms. Upper gastrointestinal symptoms have
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also been associated with significant costs due to lost work productivity [4,5], with those
suffering symptoms having an 85% (95% confidence interval, 40%-145%) increased odds of
work absenteeism [5], 27% reporting at least one day of reduced or no productivity over a 3-
month period, and 89% of this subset of people reported more than one day affected [4]. In
addition to these direct and indirect costs, increased intangible costs (pain and suffering) are
also an important repercussion of upper gastrointestinal symptoms [6], with these symptoms
shown to be associated with significantly impaired wellbeing and patients’ ability to perform
activities of daily life (subjects reporting relevant upper gastrointestinal symptoms had
significantly worse Psychological General Well-Being Index (PGWBI) and Interference with
Daily Life Index (IDLI) scores compared with those reporting no or non-relevant symptoms
(PGWBI score 65.24 versus 77.91, p<0.0001; IDLI score 75.85 versus 98.57, p<0.0001). Both
cardiovascular disease and upper gastrointestinal symptoms are common diagnoses in daily
practice. According to the American Academy of Family Physicians, numerous diagnosis
codes for both cardiovascular disease and upper gastrointestinal symptoms are among the
most frequently billed for [7].
In addition, cardiovascular and upper gastrointestinal disorders are among the top 20 leading
diagnoses for direct health expenditures in the United States [2]. In 2008, approximately $95.6
billion dollars were spent treating heart conditions and $27.2 billion were spent treating upper
gastrointestinal disorders, making these two disease states the first and twelfth most costly
diagnoses, respectively, for direct healthcare expenditures. Since cardiovascular disease and
upper gastrointestinal symptoms are both common conditions, some overlap in the occurrence
of these conditions would naturally be expected.
Diagnosis description Diagnosis code (ICD-9-CM)
Cardiovascular disease
Atrial fibrillation 427.31
Chronic ischemic heart disease, unspec. 414.9
Heart failure, congestive, unspec. 428.0
Hypertension, benign 401.1
Hypertension, unspecified 401.9
Chest pain, unspec. 786.50
Upper gastrointestinal symptoms
Gastroenteritis, noninfectious, unspec. 558.9
Gastroesophageal reflux, no esophagitis 530.81
Nausea w/ vomiting 787.01
Table 1. International Classification of Diseases, Ninth Revision, Clinical Modification Codes for Cardiovascular Disease
and Upper Gastrointestinal Symptoms Designated in the Top 100 According to the ’Family Practice Management Short
List’ [reference 7]
Dyspepsia - Advances in Understanding and Management136
Beyond both having relatively high frequencies in daily practice and large economic burdens,
there are clinical data supporting the hypothesis that upper gastrointestinal symptoms are
more prevalent in patients with cardiovascular disease. Previous studies have found upper
gastrointestinal symptoms to occur as much as twice as often [8] in patients suffering from a
cardiovascular disease [9-13], and moreover, some upper gastrointestinal disorder may
increase patients’ risk for cardiovascular disease [14-17].
Figure 1. Cardiovascular Disease and Upper Gastrointestinal Symptoms on the List of 20 Leading Diagnoses for Direct
Healthcare Expenditures (adapted from reference 2) Bars depicts the cost each diagnosis in 2008 US$, while the labels
above the bars provides each diagnosis’ ranking in direct healthcare expenditures.
The finding of higher prevalence rates of upper gastrointestinal symptoms in patients with
cardiovascular disease may exist for a number of reasons. First, there are a host of mutual risk
factors for developing both cardiovascular disease and upper gastrointestinal symptoms
[18-37]. Next, patients experiencing both health problems often complain of similar or
overlapping symptomatology, potentially resulting in the more frequent surveillance and
diagnosis of both [38]. Related to this, some studies have suggested that common means of
investigating upper gastrointestinal symptom origin can aggravate some cardiovascular
diseases or induce cardiovascular symptoms [39,40]. Finally, polypharmacy with drugs used
to manage cardiovascular diseases can cause upper gastrointestinal symptoms [8,41-46]
resulting in decreased adherence to their medications, and a perhaps initiating a cycle of
recurrence/worsening of cardiovascular disease. Moreover, some drugs to treat upper
gastrointestinal symptoms may increase cardiovascular disease risk either directly or through
drug-drug interactions.
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The aim of this chapter is to provide a detailed discussion of the evidence suggesting and
supporting an increased risk of upper gastrointestinal symptoms in populations suffering from
cardiovascular disease.
2. Evidence supporting the link between cardiovascular disease and upper
gastrointestinal symptoms
At least a half dozen published studies [8-13] have demonstrated a link between cardiovascular
diseases and an increased risk of upper gastrointestinal symptoms. Three of these studies have
assessed the association of upper gastrointestinal symptoms with general cardiovascular
diagnosis. A recent study created two cohorts of patients derived from health insurance claims
data from the Human Capital Management Services research database over a four year period
(2001-2004)[9]. The cohorts were based upon the presence or absence of functional dyspepsia
diagnosis codes, with the control cohort (n=83,450) being matched to the functional dyspepsia
cohort (n=1,669) using a propensity score that included variables such as age, sex, marital
status, salary, among others. This study demonstrated that employees with functional
dyspepsia were 1.8-fold more likely to suffer from circulatory system disease (preva‐
lence=39.19% in those with functional dyspepsia versus 22.37% in the control group; p<0.05).
Study, year
(N=)
Study Description Key Finding
Brook 2012
(N=275,875)
Retrospective database analysis of paid
health insurance claims within the Human
Capital Management Services research
database (USA); 275,875 eligible employees,
1,669 with functional dyspepsia diagnosis
codes
Higher prevalence of circulatory system disease in
those with functional dyspepsia versus controls
(ratio=1.8:1; prevalence=39.19% in those with
functional dyspepsia versus 22.37% in the control
group; p<0.05)
Stanghellini 1999
(N=5,581)
Respondents of the Domestic/International
Gastroenterology Surveillance Study which
surveyed urban, adult populations from 10
countries representing seven geographic
areas (Canada, the USA, Switzerland, The
Netherlands, Italy, Japan and the Nordic
countries) using a study-specific symptom
checklist; prevalence rate of upper
gastrointestinal symptoms=28%
Higher odds of cardiovascular condition (OR=2.0),
myocardial/endocardial/pericardial/valve condition
(OR=2.7) or vascular (extracardiac) condition
(OR=2.8) in patients with UGIS diagnosed by a
doctor
Higher odds of self-reported cardiovascular
symptoms (OR=1.5), or myocardial/endocardial/
pericardial/valve symptoms (OR=4.4) over previous
three months in patients with UGIS
Wallander 2007
(N=17,949)
Analysis UK General Practice Research
Database to identify patients with new onset
dyspepsia in 1996; overall incidence=15.3
Higher odds of chest pain (OR: 2.4, 95%CI 2.1-2.7) or
angina (OR=1.5, 95%CI=1.2-1.8) comorbidity in
dyspepsia cohort in the year prior to index date than
control cohort
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Study, year
(N=)
Study Description Key Finding
(95%CI 15.0-15.6) per 1000 person-years
(n=6,913)
Higher odds of having first time diagnosis of chest
pain (OR=2.3, 95%CI=2.0-2.8) or angina (OR=2.7,
95%CI=1.8-4.0) in dyspepsia group in the year after
index date than in control cohort
Lohr 1986
(N=4,962)
Respondents completing a questionnaire
enrolled in the Rand Health Insurance
Experiment from six sites (Dayton, Ohio;
Seattle, Washington; Fitchburg,
Massachusetts; Franklin County,
Massachusetts; Charleston, South Carolina;
and Georgetown County, South Carolina);
prevalence rate of ulcer-like symptoms per
100 (aged 18-61 years) men=3.8 and
women=3.8
Congestive heart failure and angina were associated
with a 3.6-fold (p<0.001) and 2.9-fold (p<0.05)
higher odds of ulcer-like symptoms
LaMori 2012
(N=1,297)
Respondents to the 2009 National Health
and Wellness Survey, a nationwide (USA) self-
administered internet-based questionnaire;
prevalence rate of dyspepsia=34%
Dyspepsia more likely among patients with higher
stroke risk (CHADS2 ≥2, OR=1.15)
Patients reporting dyspepsia in addition to AF had
higher mean CHADS2 scores (1.9 vs. 1.4, p<0.05)
Laliberte 2012
(N=413,168)
Retrospective database study of Thomson
Reuters MarketScan data from 2005 and
2009 to quantify the incidence of dyspeptic
events in patients with atrial fibrillation;
median follow-up of 563 days
Incidence rate of dyspepsia was found to be 14.7 per
100-patients years
Pasini 1989
(N=NR)
Italian patients affected with congestive
heart failure and ischemic heart disease
studied to ascertain relation between
dyspeptic syndrome and acute cardiac
disorders
Data showed alterations of motility in esophagus,
stomach, duodenum in every patient and lesions of
gastric mucous membrane in more than half
AF=atrial fibrillation; FD=Functional dyspepsia; HLD=hyperlipidemia; HTN=hypertension; NA=not applicable; NR=not
reported; OR=odds ratio; UK=United Kingdom; UGIS=upper gastrointestinal symptoms; USA=United States of America
Table 2. Studies Assessing Upper Gastrointestinal Symptoms in Patients with Cardiovascular Disease
A second study, the large Domestic/International Gastroenterology Surveillance Study [8]
looked to investigate any association between upper gastrointestinal symptoms (gastroeso‐
phageal-, ulcer- or dysmotility-like) and lifestyle factors (including comorbidities) in a large
sample of patients experiencing dyspepsia in the prior 3-months. A sample of urban, adult
populations from seven geographic areas (Canada, United States, Switzerland, the Nether‐
lands, Italy, Japan and the Nordic countries) was obtained by door-to-door or telephone
recruitment. Subjects were divided into groups depending on whether gastrointestinal
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symptoms were reported and were analyzed for the association with comorbid conditions. In
total, 5,581 subjects were recruited, with 1,566 (28%) reporting relevant upper gastrointestinal
symptoms. In the previous three months, subjects reporting gastrointestinal symptoms self-
reported more general cardiovascular (odds ratio= 1.5) or vascular myocardial/endocardial/
pericardial and valve (odds ratio=4.4) symptoms or illnesses. Subjects with upper gastroin‐
testinal symptoms also had increased prevalence of clinician-diagnosed cardiovascular (odds
ratio=2.0) or myocardial/endocardial/pericardial and valve (odds ratio=2.7) conditions.
Two more large studies [10,11] have reported on a link between the prevalence of upper
gastrointestinal symptoms with angina and chest pain. The first, a cross-sectional study of
6,913 patients aged 20-79 with new diagnoses of dyspepsia and 11,036 age- and sex-matched
control patients from the United Kingdom-based General Practice Research Database,
demonstrated dyspeptic patients are at increased odds of having a diagnosis for chest pain
(odds ratio=2.4, 95% confidence interval=2.1-2.7) or angina (odds ratio=1.5, 95% confidence
interval=1.2-1.8) within the previous year. In addition, dyspeptic patients are also more likely
to receiving receive a first time diagnosis for chest pain (odds ratio=2.3, 95% confidence
interval=2.0-2.8) or angina (odds ratio=2.7, 95% confidence interval=1.8-4.0) [10]. In an older
study of 4,962 patients aged 18-61 who took part in the Rand Health Insurance Experiment, a
decade-long randomized controlled trial of the effects of alternative methods of financing
health care services, about 30% had one chronic illness, with an additional 16% having 2 or
more. Ulcer-like symptoms, defined by a previous diagnosis along with taking antacids daily,
frequent episodes of stomach pain relieved by milk, occurring one-half hour after eating or at
night, was significantly associated with angina (p<0.05) and congestive heart failure (p<0.001)
[11].
A single study sought to assess the prevalence of dyspepsia among patients with atrial
fibrillation [12]. The population (n=1,297) included a nationwide sample of American adults
(from the 2009 National Health and Wellness Survey) with atrial fibrillation divided into two
groups: those reporting dyspepsia (defined as any of the following: ulcers, abdominal bloating,
abdominal pain, gastroesophageal disease or heartburn) and those who did not. Of these atrial
fibrillation patients, 41% reported a diagnosis of a gastrointestinal condition while 34%
reported a diagnosis of dyspepsia. Patients with dyspepsia were associated with a significantly
higher mean CHADS2 score (1.9 vs. 1.4, p<0.05). Of note, while the CHADS2 score was
developed as a tool to determine atrial fibrillation patients’ risk for stroke, in this case, it can
also serve as a marker of the presence of cardiovascular diseases since 2 of 5 CHADS2 criteria
(eg, stroke and congestive heart failure) are in fact cardiovascular diseases and the remaining
3 criteria (eg, age, hypertension, diabetes) are potent risk factors for cardiovascular disease.
A retrospective database study sought to assess the risk of dyspepsia among patients with
atrial fibrillation [13]. Analysis of insurance claims from the MarketScan® database from
2005-2009 was conducted. The population (n=413,168) included patients ≥18 years at the date
of first atrial fibrillation diagnosis, with 180 days of continuous insurance coverage prior to
the index atrial fibrillation diagnosis, and no gastrointestinal event within 180 days of the index
atrial fibrillation diagnosis. The risk of dyspepsia was assessed with incidence rates (IRs; new
dyspepsia case per patient years of observation). During a mean follow-up of 563 days, the IR
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of dyspepsia for patients with atrial fibrillation was 14.7 events per 100 patient years. At
baseline, 62% of patients (n=257,357) had at least one medication which may cause gastroin‐
testinal tolerability issues. The authors conclude that atrial fibrillation was associated with a
40% risk of developing a gastrointestinal event, which was predominantly dyspepsia.
Finally in a small case series evaluating the relationship between dyspepsia and congestive
heart disease or ischemic heart disease in Italian patients, data showed alterations of motility
in the esophagus, stomach and duodenum in every cardiovascular disease patient evaluated
and lesions of the gastric mucous membrane in more than half [14].
In addition to the aforementioned data suggesting upper gastrointestinal symptoms are more
prevalent with patients with cardiovascular diseases; a body of literature suggesting upper
gastrointestinal symptoms may in fact induce cardiovascular disease has begun to take shape
[15-18]. In 2003, the first signal that gastro esophageal-like symptoms or disease could be linked
to the development of atrial fibrillation was published [15]. Clinicians in Australia looked at
18 patients with concomitant diagnoses of lone paroxysmal atrial fibrillation and gastroeso‐
phageal reflux disease and noted that after treatment with a proton pump inhibitor to treat the
upper gastrointestinal symptoms, 14 of 18 had a decrease or disappearance of at least one
paroxysmal atrial fibrillation symptom.
Since that time, 3 observational studies [16-18] have more thoroughly evaluated this link. In a
cohort study of 163,627 patients receiving care from the United States Army National Capitol
Area Military Healthcare System between 2001 and 2007 (5% had atrial fibrillation and 29%
had gastroesophageal-like symptoms), gastroesophageal symptoms were associated with an
increased risk of atrial fibrillation, even after adjusting for age, sex, race and atherosclerotic
risk factors (relative risk=1.19, 95% confidence interval=1.13-1.25) or further adjustment for
ischemic heart disease, cardiomyopathy, atrial septal defect and being status post-cardiac
bypass surgery (relative risk=1.08, 95% confidence interval=1.02-1.13) [16].
The second study [17] similarly sought to assess the relationship between gastroesophageal
reflux disease and atrial fibrillation; and the researchers assessed the risk for atrial fibrillation
over a follow-up period of greater than 11 years. A self-report survey was sent to 5,288 patients
aged 25-74 over the 6 year period of 1988-1994. Of these patients, 741 developed atrial
fibrillation. Contrary to the previous study, an inverse relationship with observed between
gastroesophageal reflux disease symptoms and atrial fibrillation risk (hazard ratio=0.81, 95%
confidence interval=0.68-0.96). However, the frequency of symptoms in those with gastroeso‐
phageal reflux (none, some, weekly, daily) was associated with an increased hazard of atrial
fibrillation (p<0.01 for overall association); with daily symptoms associated with the highest
hazard (hazard ratio=1.30, 95% Confidence interval=0.98-1.57) of developing atrial fibrillation
compared to no gastroesophageal symptoms (p=0.07 unadjusted and p>0.2 after adjustment
for confounders). The researchers cite an increase in medical attention in those experiencing
gastroesophageal reflux as a possible explanation for the lack of association between the
presence of symptoms and atrial fibrillation; hypothesizing that extra physician visits resulting
from gastroesophageal symptoms resulted in early and more frequent identification and
treatment of known atrial fibrillation risk factors, as well as a higher utilization of proton pump
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inhibitors (although the researchers did not have data medication use to test this hypothesis).
Finally, the most recently published study assessed the relationship between atrial fibrillation
and gastroesophageal reflux disease in 188 Japanese patients between 28-91 years of age [18].
Patients’ gastroesophageal reflux disease status was classified using the F-scale, a question‐
naire specifically designed to screen for gastroesophageal reflux disease. Almost half of
Study, year
(N=)
Study Description Key Finding
Weigl 2003
(N=18)
Endoscopic reports of 640 Austrian patients
searched for diagnosis of lone PAF and
mention of reflux esophagitis; 18 patients
invited to assess the effect of PPI therapy for
GERD on paroxysmal AF-related symptoms
PPI therapy led to a decrease or disappearance of
at least one PAF-related symptom in 14 of 18
patients.
Kunz 2009
(N=163,627)
Cross-sectional cohort study of adults in the
United States Army National Capitol Area
Military Healthcare System database; 7,992
patients with diagnosis of AF; 47,845 with
diagnosis of GERD
GERD associated with increased risk of AF
(RR=1.39, 95%CI=1.33-1.45; aRR=1.19,
95%CI=1.13-1.25#; aRR=1.08, 95%CI=1.02-1.13†)
Bunch 2009
(N=5,288)
Longitudinal survey study of Olmstead
County, Minnesota residents to assess long-
term risk of AF with symptomatic GERD; 2,577
(49%) reported GERD; 741 (14%) developed
AF over 11.4 year follow-up period
The presence of GERD was associated with a
decreased risk of AF (HR=0.81, 95%CI=0.68-0.96)
The frequency of symptoms in those with GERD
was associated with an increased hazard of AF
(p<0.01); with daily symptoms associated with the
highest risk (HR=1.30, 95% CI=0.98-1.57; p=0.07)
compared to none.
Shimazu 2011
(N=188)
Cross-sectional survey study of Japanese
patients completing screening questionnaire
for GERD based upon frequency of 12
common symptoms to evaluate the
relationship between AF and GERD; 46% with
AF
AF was associated with prevalence of GERD (F-
scale score≥8 points) (p<0.001 upon multivariate
analysis). The dyspeptic sub-score (2.05±0.29 vs.
0.94±0.12, p =0.018) and the total F-scale score
(3.98±0.51 vs. 2.12±0.21, p = 0.019) of AF patients
were significantly greater than those in normal
sinus rhythm.
*Widely used questionnaire in Japan to screen for gastroesophageal reflux disease based upon frequency of 12 common
symptoms
#Adjusted for age, sex, race, known atherosclerotic risk factors (hypertension, diabetes, hyperlipidemia, and tobacco use)
†Adjusted for strong correlates of AF: ischemic heart disease, cardiomyopathy, atrial septal defect, status post coronary
bypass surgery
AF= atrial fibrillation; aRR= adjusted relative risk; GERD= gastroesophageal reflux disorder; HR= hazard ratio; PAF=
paroxysmal atrial fibrillation; PPI= proton pump inhibitor; RR= relative risk; USA= United States of America
Table 3. Relationship Between Atrial Fibrillation and Gastroesophageal-Like Symptoms
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enrolled patients had a diagnosis of atrial fibrillation (n = 86), and while hypertension,
dyslipidemia or coronary artery disease were not associated with the prevalence of sympto‐
matic gastroesophageal reflux disease (defined as a total F-scale≥8 points) upon multivariate
analysis, atrial fibrillation did show a significant correlation with gastroesophageal reflux
disease (p<0.001). In addition, both the dyspeptic sub-score (p=0.018) and the total F-scale score
(p=0.019) of atrial fibrillation patients were significantly greater than those in normal sinus
rhythm.
Recognizing patients with both cardiovascular diseases and upper gastrointestinal conditions
is an important step in their medical care. As demonstrated in available evidence, the links
between the conditions are strong, and can impact therapeutic decisions.
3. Shared risk factors
The World Health Organization, World Heart Federation [1] and the American Heart Associ‐
ation [3] each agree on a set of risk factors for the development of cardiovascular diseases.
These risk factors include smoking, being overweight or obese, living a sedentary lifestyle, and
poor diet, as well as having pre-existing diagnoses of high cholesterol, hypertension and
diabetes.
In addition to significantly contributing to the risk of developing cardiovascular disease, these
same risk factors have also been found in epidemiologic studies to be associated with an
increased risk of reporting upper gastrointestinal symptoms. These risk factors are highly
prevalent both worldwide and in the United States [1,3].
Below we discuss the mechanism behind, and studies supporting, the association between
these risk factors and increased rates of upper gastrointestinal symptoms.
3.1. Current smoking
Over a billion people worldwide are thought to be current smokers. It is estimated that nearly
six million people die from tobacco-related deaths annually, and by 2030, this number is
projected to surpass 8 million. Smoking is the underlying cause of about 10% of cardiovascular
disease [1] and has been consistently found to be a strong and independent risk factor for
myocardial infarction and sudden death [2]. Similar findings have been observed with
cerebrovascular disease and smoking; with smokers having a 2 to 4 times increased risk of
stroke compared with nonsmokers [2]. Consequently, it is not surprising that a large number
of studies support the beneficial cardiovascular consequences of smoking cessation [1].
It is theorized that tobacco smoking/use induces upper gastrointestinal symptoms through its
effects on the gastric mucosa [19]. The nicotine in tobacco likely causes mucosal injury by
augmenting acid and pepsin release, causing duodenogastric reflux and producing free
radicals; while at the same time decreasing prostaglandin and mucus production. Addition‐
ally, smoking may reduce lower esophageal sphincter pressure and thus accentuate gastroe‐
sophageal-like dyspeptic symptoms.
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While not consistently shown in every study [20-22], smoking’s correlation with an increased
upper gastrointestinal symptom prevalence (compared to abstainers) has been demonstrated
to exist in a fair number of observational studies [8,20,23-25].
In an Australian study of 592 survey respondents of which 78 were dyspeptic, smoking was
found to significantly increase this risk of reporting dyspeptic symptoms by more than 100%
[19]. The Domestic/International Gastroenterology Surveillance Study also demonstrated
smoking to be associated with a significantly greater prevalence of upper gastrointestinal
symptoms (16% increase in relative risk) compared to those whom abstained from smoking;
with the results of multivariate analysis suggesting smoking’s largest negative effect was on
heartburn and regurgitation (gastroesophageal-like) symptom prevalence [8].
Similar results were observed in two studies of United States veterans. In the first study,
tobacco  use  was  found  to  be  associated  with  more  symptoms  of  dyspepsia  (odds  ra‐
tio=1.31,  95% confidence  interval,  1.03-1.66)[29].  In  the  second study,  a  62% relative  in‐
Risk Factor WorldwidePrevalence Rate*
United States
Prevalence Rate†
Current smoking 10%-31% 19.0%
Overweight
(BMI>25 kg/m2) 34% 34.6%
Obesity
(BMI>30 kg/m2) 9.8% (men)/13.8% (women) 34.6%
Insufficient physical activity
(<150 minutes of moderate physical
activity/week)
31.3% 21.0%
Poor diet patterns
(<4 of 5 DASH-diet components) N/A 79.0%
High cholesterol
(Total cholesterol >240 mg/dL) 9.7% 13.8%
High blood pressure
(≥140 SBP/≥90 DBP) 40% 33%
Diabetes
(Fasting glucose ≥126 mg/dL) 10% 11.8%
*Rates per the World Heart Federation/World Health Organization [1]
†Rates per the American Heart Association [2]
BMI=body mass index; DASH=Dietary Approaches to Stop Hypertension; DBP=diastolic blood pressure; N/A=not
available; SBP=systolic blood pressure
Table 4. Worldwide and United States-Specific Prevalence of Risk Factors for Cardiovascular Disease
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crease  in  dyspepsia  symptom  reporting  in  smokers  (41.4%)  compared  to  non-smokers
(25.6%) was observed.  Again,  as  in the Domestic/International  Gastroenterology Surveil‐
lance  Study [8],  subanalysis  of  the  latter  study suggested tobacco smoking may have a
more profound effect on heartburn and regurgitation symptoms, as evidenced by the fact
Study, Year
(N=)
Study Description Key Finding
Nandurkar 1998
(N=592)
Healthy blood donors in Sydney, Australia
completing the Bowel Symptoms Questionnaire;
prevalence rate of upper gastrointestinal
symptoms=13.2%
Smoking was an independent risk factor
for dyspeptic symptoms (OR=2.1,
95%CI=1.3-3.6)
Stranghelli 1999
(N=5,581)
Respondents of the Domestic/International
Gastroenterology Surveillance Study which
surveyed urban, adult populations from 10
countries representing seven geographic areas
(Canada, the USA, Switzerland, The Netherlands,
Italy, Japan and the Nordic countries) using a
study-specific symptom checklist; prevalence rate
of upper gastrointestinal symptoms=28%
Prevalence rate of upper gastrointestinal
symptoms were 30.8% for smokers and
26.5% for non-smokers, p=0.0003; Upon
multivariate regression analysis, p<0.05
only for the relationship between smoking
and gastroesophageal-like symptoms
(p=0.03) and not ulcer- or dysmotility-like
symptoms
Dominitz 1999
(N=1,582)
Respondents completing surveys (modified
Bowel Disease Questionnaire) at one of 4
Durham, NC, USA Veterans Administration
clinics; prevalence rate of upper gastrointestinal
symptoms=30% (general medicine) to 53%
(gastroenterology) depending on site of
recruitment
Tobacco use was significantly associated
with dyspeptic symptoms (OR=1.31,
95%CI=1.03-1.66)
Locke 1999
(N=1,524)
Cross-sectional survey study of Olmstead County,
Minnesota residents completing the
gastroesophageal reflux questionnaire;
prevalence rate of frequent upper
gastrointestinal symptoms=20%
Multivariate adjusted RR=1.3,
95%CI=0.8-2.1 for current vs. never
smokers and OR=1.6, 95% confidence
interval, 1.1-2.3 for past vs. never smoker
Shaib 2004
(N=465)
Employees of the Houston Veterans Affairs
Medical Center, Texas, USA, completing the
Gastro Esophageal Reflux Questionnaire;
prevalence rate of upper gastrointestinal
symptoms=31.4%
41.4% of dyspeptics (including those with
gastroesophageal-like symptoms) were
smokers vs. 25.6% non-dyspeptics; when
gastroesophageal-like symptoms were
excluded, no significant relationship
between dyspeptic symptoms and
smoking was seen (p=0.2)
CI=confidence interval; OR=odds ratio; RR=relative risk
Table 5. Summary of Studies Suggesting an Association Between Smoking and Upper Gastrointestinal Symptoms
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that  the  relationship  between  smoking  and  upper  gastrointestinal  symptom  prevalence
was no longer statistically significant when patients suffering gastroesophageal-like symp‐
toms (~50% of the study population) were excluded from the analysis (p=0.2). This find‐
ing  is  further  supported  by  a  survey  study conducted  in  Olmstead  County,  Minnesota
where  residents  demonstrating  current  or  past  smoking  increased  respondents’  risk  of
gastroesophageal symptoms by 30-60% [25].
3.2. Overweight or obesity
Overweight (body mass index ≥25 kg/m2) or obesity (body mass index ≥30 kg/m2) are highly
prevalent disorders worldwide and are particular problems in the United States [1,3]. Obesity
is strongly related to major cardiovascular risk factors such as elevated blood pressure, glucose
intolerance, type 2 diabetes and dyslipidemia. Prospective studies have shown a significant
relationship between overweight or obesity and an increased rate of cardiovascular events. In
a collaborative meta-analysis of 58 cohorts (221,934 people from 17 countries, 14,297 incident
cardiovascular disease outcomes, 1.87 million person-years at risk), patients’ risk of coronary
heart disease, ischemic stroke and cardiovascular disease were found to increase by 29%, 20%
and 23%, respectively, for every 4.56 kg/m2 increase in body mass index after adjustment for
age, gender, and smoking status [26].
The mechanism behind the association between overweight/obesity and increased upper
gastrointestinal symptoms is likely multifactorial [22]. First, the poor diet (ie, increased intake
of fatty foods) [22] and lack of exercise that leads the overweight/obese state also promotes
increased upper gastrointestinal symptoms (see further discussion below). Next, it is possible
that abdominal obesity may lead to gastric compression by the surrounding adipose tissue.
This causes increased intragastric pressure and relaxation of the lower esophageal sphincter,
and ultimately heartburn and regurgitation. Obesity may also lead to the development of hiatal
hernia promoting regurgitation symptoms. Lastly, humoral mechanisms related to obesity
including increased levels of insulin, leptin, growth factors or hormones may contribute to
gastrointestinal symptoms as well [22,27].
Results of the Domestic/International Gastroenterology Surveillance Study [3] suggested that
the prevalence of upper gastrointestinal symptom reporting was higher in those with larger
body mass indices. However, consistent with the proposed mechanisms listed above, it
appeared the majority of the increased symptom burden related to increased body mass was
gastroesophageal-like in nature.
In a meta-analysis of 9 studies examining the association between body mass index and
gastroesophogeal-like symptoms, six (67%) found a statistically significant association.
Furthermore, data from 8 of the 9 studies demonstrated a “dose-response relationship”
between body mass index and gastroesophageal symptoms, with an increase in the pooled
adjusted odds ratios for symptoms of 1.43 (95% confidence interval, 1.158 to 1.774) for body
mass index of 25 kg/m2 to 30 kg/m2 and 1.94 (95% confidence interval, 1.468 to 2.566) for body
mass index ≥ 30 kg/m2 [28].
Dyspepsia - Advances in Understanding and Management146
3.3. Insufficient physical activity
Current guidance [1,29] recommends all adults should do at least 150 minutes a week of
moderate-intensity aerobic physical activity, 75 minutes a week of vigorous-intensity aerobic
physical activity, or some equivalent combination of both in order to reduce their risk of heart
disease and diabetes. In fact, maintaining this level of moderate- or vigorous-intensity physical
activity each week has been associated with as much as a 30% decrease in ischemic heart disease
risk and a similar reduction (27%) in the risk of developing diabetes. Unfortunately, nearly a
third of people worldwide and a fifth of Americans do not meet this goal [1,3]. While the
mechanism behind how insufficient physical activity/sedentary lifestyle is associated with
upper gastrointestinal symptoms is unclear, it may be that there is a higher rate of overweight/
obesity in those who do not engage in enough physical activity, or the failure of inactive people
to obtain the mental (reduced stress, reduced depressive symptoms and increased cognitive
function) and bodily health benefits borne from physical activity [29].
Limited data evaluating the impact of physical activity on the prevalence of upper gastroin‐
testinal symptoms have been published in the medical literature. In an internet survey of over
UGIS=upper gastrointestinal symptoms
Figure 2. Prevalence of Upper Gastrointestinal Symptoms (By Subtype) By Body Mass Index in the Domestic/Interna‐
tional Gastroenterology Surveillance Study [3] Gastroesophogeal-like symptoms are the only symptom subtype trend‐
ing upwards with increasing body mass index
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2,500 respondents complaining of functional dyspepsia (or other gastrointestinal symptoms),
only 6% of respondents reported exercising daily, 29% reported exercising at least once a week,
and a majority (54%) claimed almost never or never exercising [30]. This was significantly less
physical activity compared to a simultaneously surveyed control population (n=1,000)
(p<0.01), suggesting that a sedentary lifestyle may be associated with an increased prevalence
of upper gastrointestinal symptoms.
3.4. Poor diet patterns
Improper or poor diet has been shown to be an important risk factor for cardiovascular disease.
From a strict cardiovascular viewpoint an ideal diet consists the consumption of ≥4.5 cups per
day of fruits and vegetables, ≥2 servings a week of fish, and ≥3 servings per day of whole grains
and no more than 36 ounces per week of sugar-sweetened beverages and 1500 mg per day of
sodium [31]. In addition, other poor diet choices such as high dietary intake of saturated fat,
trans-fat and cholesterol have also been tied to poor cardiovascular outcomes [1].
The failure to meet the above-mentioned dietary and lifestyle goals not only hinders a person’s
ability to achieve a healthy body weight, desirable cholesterol profile, and blood pressure, but
has also been linked to increased rates of upper gastrointestinal complaints. In a retrospective
database analysis [9] of employed Americans with functional dyspepsia determined by having
an ICD-9 code of 536.8x (n=1,669) and matched controls (n=83,450), those found to have a
nutritional deficiency (defined by the Agency of Healthcare Research and Quality’s Clinical
Classifications Software grouping of relevant ICD-9 codes) were 3.8-times as likely to complain
of dyspeptic symptoms (p<0.05). Moreover, in the previously mentioned survey study of
>2,500 respondents complaining of dyspeptic or irritable bowel symptoms and 1,000 controls
[30], the irregular eating of meals was found to be associated with increased gastrointestinal
complaints (p<0.05).
A handful of observational studies have also more specifically evaluated the individual
contributions of various components of poor diet on upper gastrointestinal symptom preva‐
lence. An insufficient intake of vegetables has been found to be statistically significantly
associated with increased gastrointestinal complaints (p<0.05) [30]. Moreover, in a sample of
1,000 employees of the United States Veteran’s Administration system, a strong trend (p=0.09)
towards an increased prevalence of heartburn and regurgitation symptoms (adjusted odds
ratio=1.71, 95% confidence interval, 0.92-3.17) in those with high intake of saturated fat
(measured using the 100-item Block Food Frequency Questionnaire) was also observed [22].
3.5. High cholesterol and high blood pressure
Ten percent of the world’s adult population (and nearly 14% of the United States population)
have high cholesterol (total cholesterol ≥240 mg/dL) and more than one-third of all people have
high blood pressure (systolic and diastolic blood pressure ≥140 and 90 mm Hg, respectively),
including 77.9 million American adults. Approximately one third of the global burden of
ischemic heart disease can be attributed to high cholesterol, and each 20/10 mmHg increase in
blood pressure, starting at 115/75 mmHg, has been shown to double a patients’ risk of a
Dyspepsia - Advances in Understanding and Management148
cardiovascular event. The treatment of both high cholesterol and high blood pressure often
necessitates polypharmacy [32,33], and many of the drugs used to treat these conditions may
cause upper gastrointestinal symptoms (see further discussion below).
There are conflicting data regarding the association between high cholesterol, high blood
pressure and upper gastrointestinal symptoms. In one recent retrospective database analysis
of 4-years’ worth of data on 300,000 employees of companies in the United States-based,
patients with ICD-9 codes for functional dyspepsia symptoms (n=1,669) were found to have a
higher rate of both high cholesterol (prevalence rates of 21.2% versus 12.1%, p<0.05) and
essential hypertension (17.8% versus 12.4%, p<0.05) compared to matched controls without
upper gastrointestinal symptom coding (n=83,450) [9]. However, in a far older study examin‐
ing nearly 5,000 adults in the Rand Health Experiment, no statistically significant association
was observed between either hypercholesterolemia or hypertension and patient reporting of
“episodes or attacks of stomach pain or stomachache” in the prior 3-months [11].
3.6. Diabetes
In 2008, the global prevalence of diabetes (fasting plasma glucose ≥ 126 mg/dL) was estimated
to be 10%, resulting in approximately 1.3 million deaths. A diagnosis of diabetes increases
patients’ risk of cardiovascular disease by 2- to 3-fold, and consequently, cardiovascular
disease accounts for approximately 60% of all diabetes-related deaths [1].
Diabetes may increase peoples’ risk of having upper gastrointestinal complaints for a number
of reasons. First, many medications used to treat diabetes and hopefully reduce patient’s risk
of both cardiovascular and microvascular (retinopathy, neuropathy, nephropathy) complica‐
tions can cause upper gastrointestinal symptoms including biguanides, sulfonylureas and
alpha-glucosidase inhibitors [34]. Next, abnormal glucose regulation tends to occur in
conjunction with other cardiovascular risk factors such as obesity, elevated blood pressure,
low high-density lipoprotein cholesterol and a high triglyceride levels [1], as well as psychiatric
disorders [35]; all known to be risk factors for upper gastrointestinal symptoms. Finally, the
neuropathy associated with diabetes and resulting gastroparesis may cause diabetics to suffer
from more upper gastrointestinal problems [35]. A recent prospective cohort study of 782
individuals found that Helicobacter pylori infection (a common cause of upper gastrointestinal
symptoms) was associated with a 2.69-fold increased hazard of developing type II diabetes
(95% confidence interval=1.10-6.60) [36], suggesting the relationship between diabetes and
upper gastrointestinal symptoms may be bidirectional.
Some studies support the association between diabetes and upper gastrointestinal symptoms.
The Domestic/International Gastroenterology Surveillance Study demonstrated those suffer‐
ing from a metabolic or endocrine disorder (which would presumably include in large part,
diabetes) were 2.6- to 4.4-fold more likely to report upper gastrointestinal symptoms in the
prior three months (p<0.006)[8]. A study of Swedish type II diabetics (n=61) and non-diabetics
(n=106) asked to complete a gastrointestinal symptom checklist found type II diabetes were
more likely to report abdominal pain more often than once a month (28.3% versus 14.3%,
p<0.01) and heartburn (31.77% versus 14.0%, p<0.05) [37]. Interestingly, it appears that the
prevalence of upper gastrointestinal symptoms in diabetics may be linked to the extent/
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severity of their disease, with a large (n=1,101) cross-sectional survey study demonstrating
higher adjusted odds of frequent abdominal pain (odds ratio=1.62, 95% confidence interval,
1.02-2.58), dysmotility-like dyspepsia (odds ratio=2.01, 95% confidence interval, 1.30-3.11),
ulcer-like dyspepsia (odds ratio=1.49, 95% confidence interval, 0.90-2.45) and gastroesopha‐
geal reflux symptoms (odds ratio=2.28, 95% confidence interval, 1.54-3.38) in patients experi‐
encing a diabetes-related complication compared to those whom did not, and higher adjusted
odds of dysmotility-like dyspepsia (odds ratio=1.32, 95% confidence interval, 1.08-1.60), ulcer-
like dyspepsia (odds ratio=1.36, 95% confidence interval, 1.06-1.75) in those with poorer
hemoglobin A1c control [38].
Appropriate management of the overlapping risk factors can result in additional benefit to the
patients. Of the many care management decisions to be made between the health care
providers and the patients, an understanding of the risk factor pattern can help with the
prioritization. These overlapping risk factors may deserve a higher priority, as they will
improve both the cardiovascular and upper gastrointestinal conditions at the same time.
4. Overlapping symptomatology and surveillance
As many as 40% of people will complain of chest pain (along with associated symptoms of
nausea, palpitations and shortness of breath) at least once in their lifetime [39,48]; however,
symptoms reported by patients are typically unreliable for differentiating between chest pain
of a cardiac or gastrointestinal (ie, dyspepsia, gastroesophageal reflux, peptic ulcer disease,
pancreatitis, cholecystitis) origin [39,49]. Hence, the birth of famous adages such as, “when a
young man complains of pain in his heart, it is usually his stomach; when an old man complains of pain
in his stomach, it is usually his heart” [39]. Upper gastrointestinal symptoms, particularly
gastroesophageal- or dysmotility-like dyspeptic symptoms, are a frequent cause of non-cardiac
chest pain (ie, recurrent episodes of substernal chest pain in patients lacking a cardiac diagnosis
after a comprehensive evaluation) [39]. This likely explains why as many as 55% of chest pain
suffers presenting to the emergency room for the first time are not ultimately diagnosed with
cardiovascular disease [50], and 30% of patients undergoing coronary angiography each year
show no signs of coronary heart disease [51]. However, despite the lack of a cardiac diagnosis,
up to 80% of non-cardiac chest pain sufferers continue to experience symptoms over time, and
25%-45% continue to take antianginal medications [52]. Thus, because of the critical and
continual need to differentiate between cardiovascular disease and upper gastrointestinal
symptoms in patients with chest pain, it would seem reasonable to assume the increased
surveillance of one of these disorders would result in a higher rate of diagnosis of the other.
It has been suggested that in areas with a high prevalence of H. pylori infection, a “search and
treat” strategy for ischemic heart disease patients with dyspepsia could significantly reduce
the need for urgent postoperative endoscopy due to major gastrointestinal events [53].
However, endoscopy has been shown to induce cardiovascular complications, including
myocardial ischemia [40,41,54]. Thus, this practice may serve as an additional explanation for
the frequent diagnosis of cardiovascular disease in patients experiencing upper gastrointesti‐
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nal symptoms. An early study [54] of 110,469 upper endoscopies performed by 82 gastroen‐
terologists and 12 internists found a rate of 5 cardiopulmonary complications (not specifically
defined) per 100,000 procedures performed. However, more recent studies in patients with
stable coronary disease or those at risk for cardiovascular disease have observed much higher
rates of cardiovascular complications following endoscopy. In a study of 71 patients with stable
coronary heart disease undergoing endoscopy for evaluation for the safety of secondary
prophylaxis with aspirin, 42% of patients experienced silent ischemia and one patient had a
symptomatic event [40]. A second study utilizing data from 9 hospitals in the United States
evaluated 602 charts for patients undergoing endoscopy and deemed to be at risk for cardio‐
vascular disease. The researchers found an overall cardiovascular complication (either an
arrhythmia, hypotension, chest pain or angina equivalent, or myocardial infarction requiring
intervention and occurring within one calendar day after the endoscopy) rate of one for every
325 procedures (or 308 complications per 100,000), and a rate as high as one complication for
every 94 procedures (1,063 complications per 100,000) at the worst performing hospital [41]; a
complication rate 2- to 70-fold higher than previously reported in the medical literature.
The awareness of how the symptoms of cardiovascular diseases and upper gastrointestinal
conditions overlap can improve the differential diagnosis, thus reducing the chance of
inappropriate procedures and medications.
5. Adverse effect of cardiovascular drugs
Optimal treatment of patients with cardiovascular disease [32,33] often requires the use of
multiple medications. Consequently, at least some of the burden of upper gastrointestinal
symptoms experienced in patients suffering from cardiovascular disease may be a result of
polypharmacy. In the aforementioned Domestic/International Gastroenterology Surveillance
Study [8], the occurrence of upper gastrointestinal symptoms was significantly higher in
respondents reporting the use of a prescribed medication for another health problem com‐
pared to those not prescribed a medication (10.6% versus 6.0%, 5.1% versus 3.5% and 19.1%
versus 13.3% for gastroesophogeal-, ulcer- and dysmotility-like symptoms, respectively,
multivariate p<0.007 for all). Likewise, the use of an over-the-counter medication was also
associated with a higher rate of upper gastrointestinal symptoms in general and dysmotility-
like symptoms (19.3% versus 13.2% and 33.9% versus 24.6%; p<0.0001 for both).
Numerous drugs indicated or commonly used to treat cardiovascular diseases including
antiplatelets, antiarrhythmics, antihypertensives, antianginals, cholesterol-lowering medica‐
tions, as well as drugs to manage heart failure, diabetes and chronic kidney disease have been
linked to the development of upper gastrointestinal symptoms.
Unfortunately, drug-induced dyspepsia can be difficult to identify because of the high
background reporting of upper gastrointestinal symptoms. To overcome this problem, two
studies [42,43,45] were conducted in a Dutch prescription database of over 1.5 million
prescriptions (92 million person-years of follow-up) to identify signals for drug-induced
dyspepsia using prescription sequence symmetry analysis methods. The basic principle
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behind these types of analyses is that most patients complaining of drug-induced dyspeptic
symptoms are empirically treated with anti-ulcer and/or anti-dysmotility agents; therefore, a
drug’s propensity for causing upper gastrointestinal symptoms might be reflected in the
sequencing of anti-ulcer and/or anti-dysmotility agents relative to the other medication (eg,
an excess of patients presenting with their first prescription for an anti-ulcer or dysmotility
agent after compared to before the initiation of an index drug would suggest a possible
dyspepsia-causing effect of the index drug). These studies identified a handful of (index) drugs
to treat cardiovascular disease that were more often followed by (within 100-days), as
compared to preceded by a histmaine-2-antagonist, proton pump inhibitor, bismuth prepara‐
tion, sucralfate, cispiride or metoclopramide. Drugs used to treat heart failure were among the
drugs with the largest relative risks for upper gastrointestinal symptoms.
Cardiovascular Drug(s) Common Cardiovascular Indication(s)
Acetylsalicylic acid (and other NSAIDs) Antiplatelet
Amiodarone Antiarrhythmic
Amlodipine (and other calcium channel blockers) Antihypertensive, antianginal
Atorvastatin (and other statins) High cholesterol
Beta-blockers Antihypertensive, antianginal, heart failure
Bile acid sequestrants (less often with colesevelam) High cholesterol
Non-aspirin antiplatelet agents (ie, cilostazol, ticlopidine) Antiplatelet
Fibric acid derivatives (gemfibrozil>fenofibrate) High cholesterol
Fish oil preparations (ie, omega-3 fatty acids) High cholesterol, dietary supplement
Digoxin Atrial fibrillation, heart failure
Dronedarone Antiarrhythmic (atrial fibrillation)
Loop diuretics Heart failure, chronic kidney disease
Losartan Antihypertensive, heart failure, diabetes, chronic
kidney disease
Niacin and nicotinic acid derivatives High cholesterol
Nitrates Antianginal
Potassium supplements Dietary supplement
Ramipril (and other ACE inhibitors) Antihypertensive, heart failure, diabetes, chronic
kidney disease
This list was derived from searches of references 41,42,44,54,55
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ACE=angiotensin-converting enzyme; NSAID=non-steroidal anti-inflammatory
Table 6. Cardiovascular Drugs Commonly Associated With Upper Gastrointestinal Symptoms
While a plausible explanation or underlying mechanism by which the abovementioned
cardiovascular drugs can cause upper gastrointestinal symptoms is not always apparent, these
drugs likely induce symptoms through direct mucosal irritation or injury (ie, aspirin and other
non-steroidal anti-inflammatory drugs, potassium supplementation), facilitation of gastric
acid reflux (ie, calcium channel blockers, nitrates) or alteration of gastric motility (ie, drugs
targeting the renin-angiotensin system causing bradykinin-mediated dysmotility) [45,55]. Still
yet, other associations between cardiovascular drugs and upper gastrointestinal symptoms
may be “false” signals, representing nothing more than a link between a specific disease state
or other confounder and upper gastrointestinal symptoms. Such may be the case with
cholesterol-lowering medications. Patients with hypercholesterolemia may prefer frequent
consumption of high-fat meals a well-known independent predictors of higher gastroesopha‐
geal symptom prevalence rates. [22,42,43,45].
Similarly, while drugs commonly used to treat heart failure, including angiotensin-converting
enzyme inhibitors, angiotensin receptor blockers, loop diuretics and digoxin, have also been
demonstrated in prescription sequence symmetry analyses to be upper gastrointestinal
symptom-inducing; it is likely the symptoms attributed to them are a manifestation of heart
failure itself (which has previously been shown to increase the risk of ulcer-like symptoms by
as much as 3.6-fold [11]) and not the individual medications [11,57]. Of note, this may not
always be the case with digoxin, which has been associated with dyspeptic-like symptoms in
patients experiencing elevated/toxic blood concentrations (>2.0 ng/mL) [58].
Each year about 400,000 tons of aspirin (acetylsalicylic acid) are produced worldwide, and >50
million Americans take between 10 and 20 billion tablets for cardiovascular disease prevention
[59]. Aspirin becomes non-ionized in the acidic environment of the gastrointestinal tract
allowing it to penetrate mucosal tissue and cause irritation. Consequently it is not surprising
that numerous studies have demonstrated aspirin to increase patients’ relative risk of upper
gastrointestinal symptoms by more than 2-fold over non-users [19-21,24,44]. Because of
aspirin’s frequent use and its propensity to cause gastric mucosal injury, it is likely the biggest
drug-induced dyspepsia offender and one of the strongest links between upper gastrointesti‐
nal symptoms and cardiovascular disease. While it is best to stop aspirin in light of gastroin‐
testinal symptoms, there may be adverse cardiovascular consequences that need to be
considered. A double-blind, placebo-controlled study evaluating low-dose aspirin users who
experienced gastrointestinal bleeding compared continuation of aspirin with discontinuation
[60]. Seventy-eight patients received aspirin 80 mg daily while 78 received placebo daily for 8
weeks. All patients received intravenous followed by oral proton pump inhibitor therapy
(intravenous pantoprazole 80 mg bolus followed by 8 mg/hour for 72 hours then oral panto‐
prazole 40mg daily). Recurrent bleeding occurred in 10.3% of patients in the aspirin group vs.
5.4% of those in the placebo group (difference=4.9 points, 95% confidence interval=-3.6 to 13.4),
p=not significant), but patients who received aspirin had lower all-cause mortality rates than
patients who received placebo (1.3% vs. 12.9%, difference=11.6 points, 95% confidence
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interval=3.7 to 19.5). As such, if aspirin must be part of the regimen, like in settings where dual
antiplatelet therapy is needed (cardiac stenting, post unstable angina and myocardial infarc‐
tion), treating the adverse gastrointestinal effects may be a superior strategy.
ACE=angiotensin-converting enzyme; ARR=adjusted rate ratios; CCBs=calcium channel blockers; CI=confidence inter‐
vals; H2A=histamine-2-antagonist; PPI=proton pump inhibitor; UGIS=upper gastrointestinal symptoms
Figure 3. Results of Cardiovascular Drug Sequence Symmetry Analyses Using Histmaine-2-Antagonists, Proton Pump
Inhibitors, Bismuth Preparations or Sucralfate, Cispiride or Metoclopramide. The cardiovascular sequence symmetry
analyses depicted above assumed the development of one or more upper gastrointestinal symptoms was followed by
(within 100 days) the prescription of a drug to treat it (eg, a histmaine-2-antagonist, proton pump inhibitors, bismuth
preparation or sucralfate, cispiride or metoclopramide). Results were reported as the adjusted rate ratio of individuals
with AN upper gastrointestinal symptom-treating drug prescribed last versus individuals with the upper gastrointesti‐
nal symptom-treating drug prescribed first. Ratios above 1.0 indicate a possible upper gastrointestinal symptom-in‐
ducing effect of the index cardiovascular drug.
Of note, while studies suggest enteric-coated or buffered formulations of aspirin provide no
significant protective effect against gastrointestinal complications [61], randomized trials of
patients taking aspirin suggest concomitant proton pump inhibitor therapy can both prevent
upper gastrointestinal symptoms (p<0.05) [62] and reduce their prevalence in patients already
suffering dyspeptic symptoms [44,62].
Aspirin is not, however, the only antithrombotic agent that has been associated with upper
gastrointestinal symptoms. In fact, both non-aspirin antiplatelet agents (including other non-
steroidals, P2Y12 platelet inhibitors and phosphodiesterase inhibitors) and anticoagulants
(particularly oral direct thrombin inhibitors) have been associated with clinically important
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rates of upper gastrointestinal symptoms [46,47,63]. In the largest systematic review to date
(92 controlled trials), non-steroidals were found to increase the risk of dyspepsia versus
placebo regardless of whether a strict (relative risk=1.36, 95% confidence interval=1.11-1.67) or
liberal definition (relative risk= 1.19, 95% confidence interval=1.03-1.39) was used; with a
placebo rate of 2.3% using the strict definition and 4.2% using the liberal definition [63].
In a systematic review of randomized controlled trials of adults with atrial fibrillation receiving
pharmacologic stroke prevention, not only were upper gastrointestinal adverse effects found
to be common place, but oral direct thrombin inhibitors were associated with highest inciden‐
ces of (~11%) and drug discontinuation due to these symptoms (~2%) [46]. The Randomized
Evaluation of Long-Term Anticoagulation Therapy (RE-LY) study found a statistically higher
incidence of dyspepsia in patients receiving the oral direct thrombin inhibitor, dabigatran,
compared to adjusted-dose warfarin (11.8% for dabigatran 110 mg, 11.3% for dabigatran 150
mg and 5.8% for warfarin, p<0.001 for the comparison of either dose of dabigatran versus
warfarin)[47]. The dyspepsia-provoking nature of dabigatran has been attributed to its
formulation which utilizes a tartaric acid core to lower the pH in the gastrointestinal tract and
thus increase the absorption of the drug [47]. Luckily, there are Factor Xa inhibitors as
therapeutic alternatives to direct thrombin inhibitors in those impacted by, or likely to be
impacted by, upper gastrointestinal symptoms [56,64].
Beyond the ability of cardiovascular drugs to provoke upper gastrointestinal symptoms, the
occurrence of these symptoms may adversely affect cardiovascular drug adherence, putting
UGIS PPI Group Placebo Group
Epigastric pain 83.9% 66.7%*
Epigastric burning 72.7% 58.1%
Epigastric discomfort 68.3% 50.9%*
Heartburn 89.7% 66.7%*
Acid reflux 86.4% 56.5%*
Nausea 92.6% 78.6%
Bloating 77.9% 66.1%
*p≤0.05
PPI=proton pump inhibitor; UGIS=upper gastrointestinal symptoms
Table 7. Percentages of Patients Taking Aspirin (75-325 mg/day) and Suffering Upper Gastrointestinal Symptoms
Reporting Resolution of Symptoms Following 26-Weeks of Proton Pump Inhibitor (Esomeprazole 20 mg/day) Therapy
or Placebo [62]
Upper Gastrointestinal Symptoms and Cardiovascular Disease
http://dx.doi.org/10.5772/56564
155
patients at risk for adverse cardiovascular outcomes. Studies have demonstrated that gastro‐
intestinal side effects decrease medication adherence [66], and this likely plays an important
role in the poor adherence often seen across the spectrum cardiovascular medications [67].
6. Cardiovascular disease associated with upper gastrointestinal symptom
drug use
In addition to cardiovascular drugs provoking upper gastrointestinal symptoms, a number of
medications used to treat upper gastrointestinal symptoms have impacted cardiovascular
drug function or have been associated with poor cardiovascular outcomes through both
indirect and direct mechanisms.
6.1. Drug interactions impeding cardiovascular drug function
Proton pump inhibitors are frequently used to treat various gastrointestinal symptoms/
conditions including H. pylori infection. American College of Gastroenterology guidelines
recommended strategies for the eradication of H. pylori infection include treatment with at
Agent Mechanism of Action UGIS Nausea
Antiplatelet agents
ASA Blockade of COX-1 ++++ (>6%) ++++ (>6%)
Non-ASA NSAIDs Blockade of COX-1 +++ (ibuprofen, naproxen: 2-3%);
++++ (indomethacin: >6%)
+++/++++
(drug dependent: 3-9%)
Cilostazol PDE III blockade ++++ (~6%) ++++ (~7%)
Clopidogrel P2Y12 inhibition ++ (<2%) ++ (<2%)
Prasugrel P2Y12 inhibition ++ (<2%) +++ (~5%)
Ticagrelor P2Y12 inhibition ++ (~2%) +++ (~4%)
Ticlopidine P2Y12 inhibition ++++ (~7%) ++++ (~7%)
Anticoagulant agents
Warfarin Vitamin K antagonist ++++ (6%) ++ (1.5%)
Dabigatran Direct thrombin inhibition ++++ (11%) NA
Rivaroxaban Factor Xa inhibition ++ (≤2%) ++ (2%)
Apixaban Factor Xa inhibition NA +++ (3%)
++=minimal risk (≤2%); +++=moderate risk (3-5%); ++++=high risk (5-10%)
ASA=aspirin; COX=cyclooxygenase; NSAID=non-steroidal anti-inflammatory drug; NA=not available; PDE=phospho‐
diesterase; UGIS=upper gastrointestinal symptoms
Table 8. Cross-Comparison of Upper Gastrointestinal Symptoms Precipitated by Antithrombotics [46,47,56,65]
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least three drugs, and yield eradication rates of up to 90%. While the best H. pylori treatment
regimen may vary depending on patient characteristics, guidelines recommended four
different drug regimens including a proton pump inhibitor, clarithromycin, and amoxicillin,
or metronidazole (clarithromycin-based triple therapy) for 14 days, a proton pump inhibitor
or histamine-2-antagonist, bismuth, metronidazole, and tetracycline (bismuth quadruple
therapy) for 10–14 days, or sequential therapy consisting of a proton pump inhibitor and
amoxicillin for 5 days followed by a proton pump inhibitor, clarithromycin, and tinidazole for
an additional 5 days (as an alternative to clarithromycin-based triple or bismuth quadruple
therapy) [68].
Proton pump inhibitors competitively inhibit the cytochrome P450 2C19 isoenzyme
(CYP2C19). Based on in vitro and in vivo data, omeprazole and esomeprazole are the most
potent CYP2C19 inhibitors [69]. In vivo, omeprazole and esomeprazole induced 4 and 10 fold
functional inhibition of CYP2C19 versus less than 1.5 fold inhibition with lansoprazole and
pantoprazole [70]. Rabeprazole has in vitro data showing less inhibition of CYP2C19 than
omeprazole and lansoprazole but no in vivo data is available [69].
Clopidogrel is a CYP2C19 substrate and needs to be activated by this isoenzyme. When given
concurrently with proton pump inhibitors, there is a reduction in the produced active form of
clopidogrel and greater platelet reactivity (less platelet inhibition) [71,72].
Whether this platelet reactivity effect impacts clinical events has been controversial. A 2009
population-based study among Ontario residents aged 66 years or older used prescription
records to ascertain proton pump inhibitor use during clopidogrel therapy. The analysis
suggested that proton pump inhibitor use may be associated with an increased risk of
cardiovascular events [odds ratio for recurrent myocardial infarction within 90 days following
hospital discharge, 1.27 (1.03 to 1.57)], however, no effect on the risk of death was observed
[odds ratio of death within 90 days following hospital discharge 0.82 (0.57 to 1.18)] [73]. The
16,718 patient Clopidogrel Medco Outcomes Study was a cohort evaluation from an integrated
medical and pharmacy claims database. Patients had a clopidogrel prescription filled within
one month of a coronary stenting procedure (where dual aspirin and clopidogrel therapy is
frequently employed). Patients who concomitantly received a proton pump inhibitor were in
the active group while those without were in the control group in this observational non‐
randomized study. Those receiving a proton pump inhibitor had more cardiovascular events
(myocardial infarction, unstable angina, repeat coronary procedure) than those without (25%
vs. 18%, p<0.0001). Without randomization, however, it cannot be ascertained where it was
the underlying patient population with gastrointestinal symptoms that had a higher risk or if
the use of the proton pump inhibitor yielded the difference. When patients on each proton
pump inhibitor were analyzed separately, there were no differences in the percent of patients
with a cardiac event: omeprazole 25%, esomeprazole 25%, lansoprazole 24%, and pantoprazole
29%. Given the marked differences in CYP2C19 inhibition between omeprazole and esome‐
prazole versus lansoprazole and pantoprazole, qualitative differences between the groups
would have been expected [74]. Two other smaller analyses also supported the greater risk of
cardiac events with patients receiving concurrent proton pump inhibitors but again, whether
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the additional risk is due to the underlying differences in the populations versus the use of the
drug cannot be determined [75,76].
In the 13,608 patient TRITON-TIMI 38 Trial, a third of patients were on a concomitant proton
pump inhibitor (41% pantoprazole, 37% omeprazole, 14% esomeprazole, 10% lansoprazole,
1% rabeprazole). In a nested cohort analysis from this trial, there was no difference between
the proton pump inhibitor group and the control group for the composite endpoint of
cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke [77].
Given the profound effect of confounders, especially co-linear confounders, on the results of
observational trials, these trials cannot prove causality, regardless of their results. Randomized
and placebo controlled clinical trials eliminate many of these confounders and have much
stronger internal validity. The only major randomized evaluation of the impact of proton pump
inhibitors on cardiovascular events was the Clopidogrel and the Optimization of Gastrointes‐
tinal Events (COGENT) trial. Overall, 3761 patients starting dual antiplatelet therapy with
aspirin and clopidogrel were randomized to receive omeprazole or placebo. No difference was
found in the primary composite cardiovascular endpoint (p=0.98) but the rate of overt upper
gastrointestinal bleeding was reduced with omeprazole therapy versus placebo [hazard ratio
0.13 (0.03 to 0.56)] [78]. The use of omeprazole which is the most potent CYP2C19 inhibitor
was the best proton pump inhibitor choice to evaluate the balance of benefits to harms in this
population [56, 69].
The COGENT trial and TRITON-TIMI 38 analysis results led the American College of Cardi‐
ology, American College of Gastroenterology, and American Heart Association to issue
guidelines calling for the use of proton pump inhibitors when indicated for patients receiving
antiplatelet therapy for cardiovascular disease [79]. However, the package insert recommends
avoiding the use moderate to strong CYP2C19 inhibitors and to use alternative acid suppress‐
ing agents such as H2 antagonists or less potent CYP2C19 inhibiting proton pump inhibitors
where possible [56].
Aside from proton pump inhibitors, the histamine-2 antagonist cimetidine is ubiquitous
moderate CYP 1A2, 2C19, 2D6, and 3A4 inhibitor [56]. It raises the concentrations of all these
cardiovascular medications increasing the chances for cardiovascular adverse effects. As such
additional monitoring is suggested when added to amiodarone, beta-blockers (carvedilol,
nebivolol), calcium channel clockers (verapamil, diltiazem, nifedipine), procainamide,
propafenone, and ranolazine while selection of an alternative agent is specifically suggested
when quinidine is being used. Other drugs in this class do not have the same potency of
inhibition and are therapeutic alternatives [56].
6.2. QTc prolongation and Torsade de Pointes
Two classes of commonly used upper gastrointestinal drugs impact QTc prolongation and
arrhythmogenesis. The QTc interval is a marker of ventricular depolarization and repolariza‐
tion time and if the QTc interval reaches 500ms or is elevated by 60ms over baseline values,
the risk of the polymorphic ventricular arrhythmia Torsade de Pointes is elevated [80]. Torsade
de Pointes can be a life threatening arrhythmia and requires prompt detection and treatment.
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Cisapride is a promotility agent that enhances acetylcholine release at the myenteric plexus
[56]. In March of 2000, the Food and Drug Administration was notified that the manufacturer
would stop widespread manufacture of the drug due to elevated risk of QTc interval prolon‐
gation and the formation of the polymorphic ventricular tachycardia Torsade de Pointes. There
are 341 reports of heart rhythm abnormalities, likely Torsade de Pointes, and 80 deaths with
cisapride. It is still being made and distributed to individuals for whom other options have
failed but is contraindicated with QTc interval prolonging agents such as Vaughn Williams
Class Ia (quinidine, procainamide) or Class III (amiodarone, dronedarone, sotalol, dofetilide)
antiarrhythmic agents, macrolide antibiotics (erythromycin, clarithromycin, troleandomycin),
nefazodone, HIV protease inhibitors, and -azole antifungals. It is also contraindicated with
potent CYP3A4 inhibitors and prone individuals [56, 80]. While not classically considered a
gastrointestinal drug, erythromycin stimulates motilin receptors and can be an adjunctive
promotility agent in diabetic gastroparesis. Erythromycin blocks the rapid component of the
delayed rectifier potassium channel and prolongs the QTc interval and arrhythmogenic risk
as well [80].
The 5HT3 antagonists (dolasetron, granisetron, etc) prolong the QTc interval and when used
intravenously or in patients with other QTc interval prolonging drugs, hypokalemia or
hypomagnesemia, or congenital long QT syndrome; can induce the polymorphic ventricular
arrhythmia known as Torsade de Pointes [80]. Correcting electrolyte abnormalities before
starting a 5HT3 antagonist is important in preventing Torsade de Pointes but is also sometimes
difficult given the emesis the drugs are being used to control [56].
6.3. Bradycardia and atrioventricular blockade
The 5HT3 antagonists (dolasetron, granisetron, ondansetron, etc) and the histamine 2 receptor
antagonists (cimetidine, ranitidine) have been shown to rarely cause negative chronotropic
(reduced sinoatrial nodal firing rate) and dromotropic (reduced rate of impulse passage
through the atrioventricular node) effects when used in excessive doses or in intravenous
forms [56, 80]. Patients who are prone to develop bradycardia or heart block, such as those
with borderline low heart rates, elevated baseline PR intervals, or are receiving other negative
chronotropic or dromotropic drugs (beta-blockers, nondihydropyridine calcium channel
blockers, digoxin, Vaughn Williams Class Ic antiarrhythmic agents) are most at risk [56,80].
6.4. Hypertension
Metoclopramide is a complex dopaminergic agent with differing effects on blood pressure in
different individuals. When used as a sole agent in normotensive, essential hypertensive, and
type 2 diabetic subjects, there is no effect on systolic or diastolic blood pressure [81,82].
However, it can profoundly elevate blood pressure in patients with pheochromocytoma and
in patients developing serotonin syndrome while taking metoclopramide with select serotonin
reuptake inhibitors [83-86]. In addition, it has been shown to modestly attenuate the antihy‐
pertensive effects of bromocriptine and labetolol [87,88]. In this way, metoclopramide can
induce hypertensive urgencies and emergencies in prone individuals and alternative agents
should be utilized when appropriate.
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The consequences of these drug-disease interactions can be dire, with significant impact on
mortality and morbidities. As many of these interactions are unknown until a large population
has been using the offending medications, health care providers must remain vigilant in
identifying potential new problems.
7. Conclusions
There is growing evidence that patients with cardiovascular disease suffer a higher burden of
upper gastrointestinal symptoms and even that certain upper gastrointestinal complaints can
induce or promote cardiovascular disease. Knowledge of how these common conditions are
connected can bring forth therapeutic advantages. For instance, among patients with upper
gastrointestinal symptoms, their interactions with the health care system can increase the
chance of earlier diagnosis of cardiovascular conditions. Conversely, among patients with car‐
diovascular conditions, health care providers’ inquiry into gastrointestinal symptoms and side
effects of medications may aid in appropriate choice of therapy to enhance effectiveness and
patient adherence. Additional research is needed to clarify whether the cardiovascular pa‐
tients’ increased risk of upper gastrointestinal symptoms is a result of shared pathophysiology
or risk factors, increased surveillance due to overlapping symptoms, or induced by the fre‐
quent need for polypharmacy among suffers of both these disease states.
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